Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytomedix

This article was originally published in The Gray Sheet

Executive Summary

Deerfield, Illinois firm raises $14.7 mil in equity financing from Fusion Capital Fund II. Proceeds will go towards "general corporate purposes, acquisitions and other opportunities," according to a release. Cytomedix' current product offering include the Autologel and ProCuren wound healing agents, composed of naturally occurring growth factors. Applications include treatment of diabetic foot ulcers, venous stasis and pressure ulcers. Separately on April 26, the firm raised $2.1 mil. in convertible bond financing, with a potential of raising up to $6.5 mil. Funds will go towards paying off other debt securities, including bridge financing obtained in connection with the January 2001 purchase of assets from Curative Health Services, maker of the ProCuren product
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel